The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Mohammed AA. Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study. Ann Med Surg. 2019;48:129–134. doi:10.1016/j.amsu.2019.11.005
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3(11):821–831. doi:10.1038/nrc1211
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). doi:10.1093/jnci/dju055
   PubMedGoogle Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869–10874. doi:10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Fonatsch C, Duchrow M, Rieder H, et al. Assignment of the human Ki-67 gene (MK167) to 10q25-qter. Genomics. 1991;11(2):476–477. doi:10.1016/0888-7543(91)90163-9
   PubMed Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710–1715. doi:10.4049/jimmunol.133.4.1710
   PubMed Web of Science ®Google Scholar
• Andre F, Arnedos M, Goubar A, Ghouadni A, Delaloge S. Ki67--no evidence for its use in node-positive breast cancer. Nat Rev Clin Oncol. 2015;12(5):296–301. doi:10.1038/nrclinonc.2015.46
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–1664. doi:10.1093/jnci/djr393
   PubMed Web of Science ®Google Scholar
• Prat A, Cheang MC, Martin M, et al. PPrognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203–209. doi:10.1200/JCO.2012.43.4134
   PubMed Web of Science ®Google Scholar
• Kreipe H, Harbeck N, Christgen M. Clinical validity and clinical utility of Ki67 in early breast cancer. Ther Adv Med Oncol. 2022;14:17588359221122725. doi:10.1177/17588359221122725
   Web of Science ®Google Scholar
• Polley MY, Leung SC, Mcshane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105(24):1897–1906. doi:10.1093/jnci/djt306
   PubMedGoogle Scholar
• Stålhammar G, Robertson S, Wedlund L, et al. Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. Histopathology. 2018;72(6):974–989. doi:10.1111/his.13452
   PubMed Web of Science ®Google Scholar
• Wang YX, Wang YY, Yang CG, et al. An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer. Breast. 2020;49:225–232. doi:10.1016/j.breast.2019.12.009
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–1329. doi:10.1093/annonc/mdp322
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–750. doi:10.1093/jnci/djp082
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736–1747. doi:10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–2223. doi:10.1093/annonc/mdt303
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies--improving the management of early breast cancer: st Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–1546. doi:10.1093/annonc/mdv221
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Curigliano G, Thurlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–1235. doi:10.1016/j.annonc.2021.06.023
   PubMed Web of Science ®Google Scholar
• Gallardo A, Garcia-Valdecasas B, Murata P, et al. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis. Breast Cancer Res Treat. 2018;167(1):31–37. doi:10.1007/s10549-017-4486-z
   PubMed Web of Science ®Google Scholar
• Alco G, Bozdogan A, Selamoglu D, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett. 2015;9(3):1046–1054. doi:10.3892/ol.2015.2852
   PubMed Web of Science ®Google Scholar
• Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–371. doi:10.1007/s10549-016-3817-9
   PubMed Web of Science ®Google Scholar
• Maranta AF, Broder S, Fritzsche C, et al. Do you know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast. 2020;51:120–126. doi:10.1016/j.breast.2020.03.005
   PubMed Web of Science ®Google Scholar
• Abubakar M, Orr N, Daley F, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18(1):104. doi:10.1186/s13058-016-0765-6
   PubMedGoogle Scholar
• Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477–491. doi:10.1007/s10549-015-3559-0
   PubMed Web of Science ®Google Scholar
• Breast Cancer Professional Committee of Chinese Anti-Cancer Association. Guidelines and norms for diagnosis and treatment of Breast Cancer of Chinese Anti-Cancer Association (2019 Edition). China Oncology. 2019;29(8):609–679. doi:10.19401/j.cnki.1007-3639.2019.08.009
   Google Scholar
• Burstein HJ. Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med. 2020;383(26):2557–2570. doi:10.1056/NEJMra1307118
   PubMed Web of Science ®Google Scholar
• Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700–1712. doi:10.1093/annonc/mdx308
   PubMed Web of Science ®Google Scholar
• Liang Q, Ma D, Gao RF, et al. Effect of Ki-67 expression levels and histological grade on breast cancer early relapse in patients with different immunohistochemical-based subtypes. Sci Rep. 2020;10(1):7648. doi:10.1038/s41598-020-64523-1
   PubMed Web of Science ®Google Scholar
• Yang YL, Guo XJ, Fu L. Interpretation and analysis of the results of main molecular pathological indexes of Breast Cancer. Chin J Pathol. 2020;49(5):526–528. doi:10.3760/cma.j.cn112151-20190917-00507
   Google Scholar
• Oddo D, Pulgar D, Elgueta N, et al. Can histological grade and mitotic index replace Ki67 to determine luminal breast cancer subtypes? Asian Pac J Cancer Prev. 2018;19(1):179–183. doi:10.22034/APJCP.2018.19.1.179
   PubMedGoogle Scholar